The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation
Abstract
PURPOSE: To explore the relationship between oral mucositis and selected clinical and economic outcomes in blood and marrow transplant patients. PATIENTS AND METHODS: Subjects consisted of 92 transplant patients from eight centers who participated in a multinational pilot study of a new oral mucositis scoring system (Oral Mucositis Assessment Scale [OMAS]). In the pilot study, patients were evaluated for erythema and ulceration/pseudomembrane formation beginning on the first day of conditioning and continuing for 28 days. We examined the relationship between patients’ peak OMAS scores and days with fever (body temperature > 38.0°C), the occurrence of significant infection, days of total parenteral nutrition (TPN), and days of injectable narcotic therapy (all over 28 days), days in hospital (over 60 days), total hospital charges for the index admission, and vital status at 100 days. RESULTS: Patients’ peak OMAS scores spanned the full range of possible values (0 to 5) and were significantly (P < .05) correlated with all of the outcomes of interest except days with fever (P = .21). In analyses controlling for type of graft (autologous v allogeneic) and study center, a 1-point increase in peak OMAS score was associated with (1) 1.0 additional day with fever (P < .01), (2) a 2.1-fold increase in risk of significant infection (P < .01), (3) 2.7 additional days of TPN (P < .0001), (4) 2.6 additional days of injectable narcotic therapy (P < .0001), (5) 2.6 additional days in hospital (P < .01), (6) $25,405 in additional hospital charges (P < .0001), and (7) a 3.9-fold increase in 100-day mortality risk (P < .01). Mean hospital charges were $42,749 higher among patients with evidence of ulceration compared with those without (P = .06). CONCLUSION: Oral mucositis is associated with significantly worse clinical and economic outcomes in blood and marrow transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sonis, S. T., Eilers, J. P., Epstein, J. B., LeVeque, F. G., Liggett, W. H., Mulagha, M. T., Peterson, D. E., Rose, A. H., Schubert, M. M., Spijkervet, F. K., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990515)85:10<2103::aid-cncr2>3.0.co;2-0 · Cited by 403
Self-citationElting, L. S., Bodey, G. P., & Keefe, B. H. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.6.1201 · Cited by 377
Patient reports of complications of bone marrow transplantation
Bellm, L. A., Epstein, J. B., Rose-Ped, A., Martin, P., & Fuchs, H. J. (2000) · Supportive Care in Cancer · doi:10.1007/s005209900095 · Cited by 366
Self-citationClassen, D. C., Burke, J. P., Ford, C. D., Evershed, S., Aloia, M. R., Wilfahrt, J. K., & Elliott, J. A. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90373-l · Cited by 97
Cited by
Sonis, S. T., Elting, L. S., Keefe, D., Peterson, D. E., Schubert, M., Hauer-Jensen, M., Bekele, B. N., Raber-Durlacher, J., Donnelly, J. P., Rubenstein, E. B., et al. (2004) · Cancer · doi:10.1002/cncr.20162 · Cited by 1,417
Self-citationSonis, S. T. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1318 · Cited by 1,361
Self-citationMASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., Bowen, J., Gibson, R., Saunders, D. P., Zadik, Y., et al. (2020) · Cancer · doi:10.1002/cncr.33100 · Cited by 1,336
Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
Spielberger, R., Stiff, P., Bensinger, W., Gentile, T., Weisdorf, D., Kewalramani, T., Shea, T., Yanovich, S., Hansen, K., Noga, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040125 · Cited by 893
Rubenstein, E. B., Peterson, D. E., Schubert, M., Keefe, D., McGuire, D., Epstein, J., Elting, L. S., Fox, P. C., Cooksley, C., Sonis, S. T., et al. (2004) · Cancer · doi:10.1002/cncr.20163 · Cited by 820
Self-citationThe burdens of cancer therapy: Clinical and economic outcomes of chemotherapy‐induced mucositis
Elting, L. S., Cooksley, C., Chambers, M., Cantor, S. B., Manzullo, E., & Rubenstein, E. B. (2003) · Cancer · doi:10.1002/cncr.11671 · Cited by 617
Management of Oral Mucositis in Patients Who Have Cancer
Lalla, R. V., Sonis, S. T., & Peterson, D. E. (2008) · Dental Clinics of North America · doi:10.1016/j.cden.2007.10.002 · Cited by 602
Self-citationTaplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J., Gleason, C., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K. V., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00374 · Cited by 601
Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., Cohen, G. I., Emami, B., Gradishar, W. J., Mitchell, R. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2627 · Cited by 540
Mucositis: The impact, biology and therapeutic opportunities of oral mucositis
Sonis, S. T. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2009.08.006 · Cited by 525
Radiation-Induced Oral Mucositis
Maria, O. M., Eliopoulos, N., & Muanza, T. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00089 · Cited by 455
Flowers, C. R., Seidenfeld, J., Bow, E. J., Karten, C., Gleason, C., Hawley, D. K., Kuderer, N. M., Langston, A. A., Marr, K. A., Rolston, K. V. I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8661 · Cited by 448
The Role of Intestinal Microbiota in the Development and Severity of Chemotherapy-Induced Mucositis
van Vliet, M. J., Harmsen, H. J. M., de Bont, E. S. J. M., & Tissing, W. J. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000879 · Cited by 436
Vera‐Llonch, M., Oster, G., Hagiwara, M., & Sonis, S. (2006) · Cancer · doi:10.1002/cncr.21622 · Cited by 388
Self-citationPrevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
On behalf of The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO), Zadik, Y., Arany, P. R., Fregnani, E. R., Bossi, P., Antunes, H. S., Bensadoun, R.-J., Gueiros, L. A., Majorana, A., Nair, R. G., et al. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04890-2 · Cited by 367
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
Nucci, M., & Anaissie, E. (2009) · Clinical Infectious Diseases · doi:10.1086/605664 · Cited by 347
Castagnola, E., Fontana, V., Caviglia, I., Caruso, S., Faraci, M., Fioredda, F., Garre, M. L., Moroni, C., Conte, M., Losurdo, G., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/522533 · Cited by 292
van Vliet, M. J., Tissing, W. J. E., Dun, C. A. J., Meessen, N. E. L., Kamps, W. A., de Bont, E. S. J. M., & Harmsen, H. J. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599346 · Cited by 267
Topuz, E., Derin, D., Can, G., Kürklü, E., Çınar, S., Aykan, F., Çevikbaş, A., Dişçi, R., Durna, Z., Şakar, B., et al. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9171-y · Cited by 49
“CT causes DNA damage in basal epithelial cells and generates reactive oxygen species (ROS) [4, 5].”
Background
Metadata
- Authors
- Sonis, S. T., Oster, G., Fuchs, H., Bellm, L., Bradford, W. Z., Edelsberg, J., Hayden, V., Eilers, J., Epstein, J. B., LeVeque, F. G., Miller, C., Peterson, D. E., Schubert, M. M., Spijkervet, F. K. L., & Horowitz, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-04-15
- Volume
- 19
- Issue
- 8
- Pages
- 2201-2205
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1788256932
- Cited by
- 678
- References
- 4
- FWCI
- 17.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.